192 related articles for article (PubMed ID: 37235690)
1. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Al Malki MM; London K; Baez J; Akahoshi Y; Hogan WJ; Etra A; Choe H; Hexner E; Langston A; Abhyankar S; Ponce DM; DeFilipp Z; Kitko CL; Adekola K; Reshef R; Ayuk F; Capellini A; Chanswangphuwana C; Eder M; Eng G; Gandhi I; Grupp S; Gleich S; Holler E; Javorniczky NR; Kasikis S; Kowalyk S; Morales G; Özbek U; Rösler W; Spyrou N; Yanik G; Young R; Chen YB; Nakamura R; Ferrara JLM; Levine JE
Blood Adv; 2023 Sep; 7(17):5189-5198. PubMed ID: 37235690
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.
Kekre N; Kim HT; Hofer J; Ho VT; Koreth J; Armand P; Nikiforow S; Gooptu M; Romee R; Alyea EP; Nageshwar P; Glotzbecker B; El-Jawahri A; DeFilipp Z; Soiffer RJ; Antin JH; Chen YB; Cutler C
Bone Marrow Transplant; 2021 May; 56(5):1006-1012. PubMed ID: 32895491
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract.
Ponce DM; Alousi AM; Nakamura R; Slingerland J; Calafiore M; Sandhu KS; Barker JN; Devlin S; Shia J; Giralt S; Perales MA; Moore G; Fatmi S; Soto C; Gomes A; Giardina P; Marcello L; Yan X; Tang T; Dreyer K; Chen J; Daley WL; Peled JU; van den Brink MRM; Hanash AM
Blood; 2023 Mar; 141(12):1389-1401. PubMed ID: 36399701
[TBL] [Abstract][Full Text] [Related]
6. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Gatza E; Braun T; Levine JE; Ferrara JL; Zhao S; Wang T; Chang L; Harris A; Pawarode A; Kitko C; Magenau JM; Yanik GA; Couriel DR; Goldstein S; Connelly J; Reddy P; Paczesny S; Choi SW
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1426-34. PubMed ID: 24892263
[TBL] [Abstract][Full Text] [Related]
7. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Murata M; Nakasone H; Kanda J; Nakane T; Furukawa T; Fukuda T; Mori T; Taniguchi S; Eto T; Ohashi K; Hino M; Inoue M; Ogawa H; Atsuta Y; Nagamura-Inoue T; Yabe H; Morishima Y; Sakamaki H; Suzuki R
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1183-9. PubMed ID: 23676716
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.
Gergoudis SC; DeFilipp Z; Özbek U; Sandhu KS; Etra AM; Choe HK; Kitko CL; Ayuk F; Aziz M; Baez J; Ben-David K; Bunworasate U; Gandhi I; Hexner EO; Hogan WJ; Holler E; Kasikis S; Kowalyk SM; Lin JY; Merli P; Morales G; Nakamura R; Reshef R; Rösler W; Srinagesh H; Young R; Chen YB; Ferrara JLM; Levine JE
Blood Adv; 2020 Dec; 4(24):6098-6105. PubMed ID: 33351103
[TBL] [Abstract][Full Text] [Related]
9. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
Lee SJ; Zahrieh D; Agura E; MacMillan ML; Maziarz RT; McCarthy PL; Ho VT; Cutler C; Alyea EP; Antin JH; Soiffer RJ
Blood; 2004 Sep; 104(5):1559-64. PubMed ID: 15138163
[TBL] [Abstract][Full Text] [Related]
10. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
Levine JE; Braun TM; Harris AC; Holler E; Taylor A; Miller H; Magenau J; Weisdorf DJ; Ho VT; Bolaños-Meade J; Alousi AM; Ferrara JL;
Lancet Haematol; 2015 Jan; 2(1):e21-9. PubMed ID: 26687425
[TBL] [Abstract][Full Text] [Related]
11. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G
Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
Zeiser R; Socié G; Schroeder MA; Abhyankar S; Vaz CP; Kwon M; Clausen J; Volodin L; Giebel S; Chacon MJ; Meyers G; Ghosh M; Deeren D; Sanz J; Morariu-Zamfir R; Arbushites M; Lakshminarayanan M; Barbour AM; Chen YB
Lancet Haematol; 2022 Jan; 9(1):e14-e25. PubMed ID: 34971577
[TBL] [Abstract][Full Text] [Related]
13. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
Fuji S; Inoue Y; Utsunomiya A; Moriuchi Y; Uchimaru K; Choi I; Otsuka E; Henzan H; Kato K; Tomoyose T; Yamamoto H; Kurosawa S; Matsuoka K; Yamaguchi T; Fukuda T
J Clin Oncol; 2016 Oct; 34(28):3426-33. PubMed ID: 27507878
[TBL] [Abstract][Full Text] [Related]
14. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
Major-Monfried H; Renteria AS; Pawarode A; Reddy P; Ayuk F; Holler E; Efebera YA; Hogan WJ; Wölfl M; Qayed M; Hexner EO; Wudhikarn K; Ordemann R; Young R; Shah J; Hartwell MJ; Chaudhry MS; Aziz M; Etra A; Yanik GA; Kröger N; Weber D; Chen YB; Nakamura R; Rösler W; Kitko CL; Harris AC; Pulsipher M; Reshef R; Kowalyk S; Morales G; Torres I; Özbek U; Ferrara JLM; Levine JE
Blood; 2018 Jun; 131(25):2846-2855. PubMed ID: 29545329
[TBL] [Abstract][Full Text] [Related]
15. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
Qayed M; Kapoor U; Gillespie S; Westbrook A; Aguayo-Hiraldo P; Ayuk FA; Aziz M; Baez J; Choe H; DeFilipp Z; Etra A; Grupp SA; Hexner E; Holler E; Hogan WJ; Kowalyk S; Merli P; Morales G; Nakamura R; Pulsipher MA; Schechter T; Shah J; Spyrou N; Srinagesh HK; Wölfl M; Yanik G; Young R; Kitko CL; Ferrara JLM; Levine JE
Transplant Cell Ther; 2024 Jun; 30(6):603.e1-603.e11. PubMed ID: 38548227
[TBL] [Abstract][Full Text] [Related]
16. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Jagasia M; Perales MA; Schroeder MA; Ali H; Shah NN; Chen YB; Fazal S; Dawkins FW; Arbushites MC; Tian C; Connelly-Smith L; Howell MD; Khoury HJ
Blood; 2020 May; 135(20):1739-1749. PubMed ID: 32160294
[TBL] [Abstract][Full Text] [Related]
18. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.
Akahoshi Y; Spyrou N; Hoepting M; Aguayo-Hiraldo P; Ayuk F; Chanswangphuwana C; Choe HK; Eder M; Etra AM; Grupp SA; Hexner EO; Hogan WJ; Kitko CL; Kraus S; Al Malki MM; Merli P; Qayed M; Reshef R; Schechter T; Ullrich E; Vasova I; Wölfl M; Zeiser R; Baez J; Beheshti R; Eng G; Gleich S; Kasikis S; Katsivelos N; Kowalyk S; Morales G; Young R; DeFilipp Z; Ferrara JLM; Levine JE; Nakamura R
Blood Adv; 2024 Apr; 8(8):2047-2057. PubMed ID: 38324721
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD).
Choe H; Ferrara JLM
Expert Opin Ther Targets; 2021 Sep; 25(9):761-771. PubMed ID: 34669521
[TBL] [Abstract][Full Text] [Related]
20. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Kennedy GA; Varelias A; Vuckovic S; Le Texier L; Gartlan KH; Zhang P; Thomas G; Anderson L; Boyle G; Cloonan N; Leach J; Sturgeon E; Avery J; Olver SD; Lor M; Misra AK; Hutchins C; Morton AJ; Durrant ST; Subramoniapillai E; Butler JP; Curley CI; MacDonald KPA; Tey SK; Hill GR
Lancet Oncol; 2014 Dec; 15(13):1451-1459. PubMed ID: 25456364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
